RESEARCH TRIANGLE PARK – Raleigh-based Merz North America has received approval from the U.S. Food and Drug Administration to market a treatment for blepharospasm, or involuntary blinking, in adults.
RALEIGH, N.C.--(BUSINESS WIRE)--Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN ® ...
Most people have suffered a minor twitch or an eye spasm that at first seems trivial. In fact, sometimes, it could be a result of fatigue or stress and cause a minor annoyance. However, in rare cases, ...
PHILADELPHIA — IncobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) conveys long-term safety and efficacy in patients with benign essential blepharospasm (BEB) who are botulinum toxin-naïve, new ...
CORONADO, California — Patients with blepharospasm can wait more than 2 years to receive a correct diagnosis, according to a new survey. "There's no excuse," said researcher Kristen Dunbar, MD, a ...
Hemifacial spasms happen when a blood vessel puts excess pressure on a facial nerve, per the National Institute of Neurological Disorders and Stroke (NINDS). They can also be caused by external nerve ...
Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback